• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Veracyte Inc. (Amendment)

    2/13/24 5:16:04 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email
    SC 13G/A 1 tv02198-veracyteinc.htm SCHEDULE 13G/A veracyteinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  Veracyte Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  92337F107

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  92337F107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    47,376

    7.  SOLE DISPOSITIVE POWER

    6,995,420

    8.  SHARED DISPOSITIVE POWER

    122,791

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,118,211

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.75%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Veracyte Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    6000 Shoreline Court, Suite 300
    South San Francisco, CA 94080

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    92337F107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $VCYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    6/2/2026$55.00Outperform
    Wolfe Research
    4/13/2026$45.00Buy
    Jefferies
    12/2/2025$48.00Underweight
    Morgan Stanley
    10/20/2025$40.00Hold
    Canaccord Genuity
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    More analyst ratings

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Veracyte with a new price target

    Wolfe Research resumed coverage of Veracyte with a rating of Outperform and set a new price target of $55.00

    6/2/26 8:39:26 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Veracyte with a new price target

    Jefferies initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

    4/13/26 9:01:55 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Morgan Stanley resumed coverage on Veracyte with a new price target

    Morgan Stanley resumed coverage of Veracyte with a rating of Underweight and set a new price target of $48.00

    12/2/25 8:36:20 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

    Genomic test using whole-transcriptome next-generation sequencing technology will be available to order on June 8 The Prosigna test predicts chemotherapy benefit and quantifies 10-year risk of recurrence to help personalize treatment decisions in patients with early-stage breast cancer On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The Prosigna test determines a patient's ROR score a

    6/1/26 7:30:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

    Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate's utility in high-risk localized disease Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the chemotherapy docetaxel to standard hormonal therapy (ADT plus enzalutamide), known as triplet therapy, and who can safely avoid it, providing the first Level 1B 1 evidence for a genomic test guiding this d

    5/30/26 8:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

    Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study shows for the first time, based on the Prosigna test results, that more than two-thirds of patients could be spared chemotherapy without compromising outcomes Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the ASCO Annual Meeting, conc

    5/29/26 3:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chief Accounting Officer Wygant Jonathan exercised 24,000 shares at a strike of $24.80 and sold $1,089,624 worth of shares (24,000 units at $45.40) (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    5/27/26 4:19:11 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Director Epstein Robert S sold $440,129 worth of shares (10,000 units at $44.01) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 52,446 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    5/22/26 4:39:11 PM ET
    $VCYT
    Medical Specialities
    Health Care

    SVP, General Counsel Mcguire Annie sold $398,211 worth of shares (10,204 units at $39.02) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 143,708 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    5/8/26 4:25:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    SEC Filings

    View All

    SEC Form 144 filed by Veracyte Inc.

    144 - VERACYTE, INC. (0001384101) (Subject)

    5/20/26 4:38:47 PM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Veracyte Inc.

    SCHEDULE 13G - VERACYTE, INC. (0001384101) (Subject)

    5/12/26 12:19:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.

    SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)

    5/6/26 11:40:41 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Financials

    Live finance-specific insights

    View All

    Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal investigators of OPTIMA, Professor of Breast Oncology at the University of Glasgow and Honorary Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, will join for the discussion. The conference call will be webcast live

    5/22/26 8:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces First Quarter 2026 Financial Results

    Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. "We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets," said Marc Stapley, Veracyte's CEO. "Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approaching an inflection point with the upcoming launc

    5/5/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/even

    4/14/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Veracyte Names Kevin Haas as Chief Development and Technology Officer

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company's global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company's end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief De

    3/16/26 4:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veracyte Inc.

    SC 13G - VERACYTE, INC. (0001384101) (Subject)

    11/12/24 9:30:49 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    11/8/24 10:41:07 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    10/2/24 2:12:30 PM ET
    $VCYT
    Medical Specialities
    Health Care